10月8日，10x Genomics盘中下跌5.26%，报72.22美元/股，成交额2616.98万美元。
公司宣布与Fred Hutchinson癌症中心达成多项目研究合作，推进实体瘤和血液癌领域的单细胞及空间技术，但该消息未能提振股价。第一个项目将使用Flex Apex和Xenium平台识别晚期膀胱癌患者的治疗反应生物标志物，第二个项目则利用Flex Apex评估急性髓系白血病治疗后残留病灶检测的改善潜力。
公司所在的生命科学工具和服务行业中，Tempus AI跌4.04%，Illumina跌3.59%，赛默飞世尔跌2.60%，安捷伦科技跌2.52%，丹纳赫跌2.07%，板块整体表现低迷。
10x Genomics是一家生命科学技术公司，专注于开发创新的产品和解决方案，以探究、理解并掌控生物学。其集成研究解决方案包括用于分析生物系统的仪器、耗材和软件。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.